Seeking Alpha

The Supreme Court will review a "pay for delay" case in which Solvay, now owned by Abbott Labs...

The Supreme Court will review a "pay for delay" case in which Solvay, now owned by Abbott Labs (ABT), paid three generic drug companies to up to $40M a year, including Watson (WPI), to postpone making copycat versions of Solvay's Androgel testosterone treatment. The case has industry wide ramifications, with the FTC saying the practice costs customers $3.5B a year. (previous)
Comments (1)
  • davidbdc
    , contributor
    Comments (3141) | Send Message
     
    This is ridiculous. If I understand this correctly, Abbott paid them an amount that might be a little less than what they would otherwise make - to allow Abbot to keep selling a drug just like it was under patent protection.

     

    Two comments - One, I hope Abbott loses. This is just plain wrong.

     

    Two, This shows just how screwed up our medical system is.

     

    Three, There obviously needs to be more generic producers. Perhaps a few of these large generic producers need to be broken up if the industry is basically an oligopoly. Break up one.

     

    Getting paid to not compete just comes across as a bribe.
    9 Dec 2012, 11:27 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|